Parimifasor
Parimifasor (LYC-30937) is an orally active agent for inflammatory bowel disease. Parimifasor targets F1F0-ATPase. Parimifasor acts on respiratory complex V, slows ATP production and induces Apoptosis. Parimifasor can be used in the research of inflammatory bowel disease[1].
Product Specifications
CAS Number
1796641-10-5
Product Name Alternative
LYC30937
UNSPSC
12352005
Hazard Statement
H302, H315, H319
Target
Apoptosis; ATP Synthase
Type
Reference compound
Related Pathways
Apoptosis; Membrane Transporter/Ion Channel
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/Parimifasor.html
Purity
98.53
Solubility
DMSO : 66.67 mg/mL (ultrasonic)
Smiles
O=C(C1=CC(Cl)=CC=C1)N/C(NC2=NNC(C(F)(F)F)=C2)=N/C3=CC(Cl)=CC(F)=C3
Molecular Formula
C18H11Cl2F4N5O
Molecular Weight
460.21
Precautions
H302, H315, H319
References & Citations
[1]Sinniger V, et al. Electrical vagus nerve stimulation as an innovative treatment in inflammatory bowel diseases[J].
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Phase 1
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
NOTCH2 (Neurogenic Locus Notch Homolog Protein 2, Notch 2, hN2) (Not for Export EU)
Anti-LINGO2 Antibody Picoband®, Cy3 Conjugate
SNAP23, CT (SNAP23, Synaptosomal-associated protein 23, Vesicle-membrane fusion protein SNAP-23) (MaxLight 750) discontinued